Titre (en)
Analysis
France
Racine
Analysis
France
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Analysis (France)

Index « Titre (en) » - entrée « factors »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
factor < factors < failed  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000007 (2020) Rakesh Awasthi [États-Unis] ; Lida Pacaud [États-Unis] ; Edward Waldron [États-Unis] ; Constantine S. Tam [Australie] ; Ulrich J Ger [Autriche] ; Peter Borchmann [Allemagne] ; Samantha Jaglowski [États-Unis] ; Stephen Ronan Foley [Canada] ; Koen Van Besien [États-Unis] ; Nina D. Wagner-Johnston [États-Unis] ; Marie José Kersten [Pays-Bas] ; Stephen J. Schuster [États-Unis] ; Gilles Salles [France] ; Richard T. Maziarz [États-Unis] ; Özlem Anak [États-Unis] ; Christopher Del Corral [États-Unis] ; Jufen Chu [États-Unis] ; Irina Gershgorin [États-Unis] ; Iulian Pruteanu-Malinici [États-Unis] ; Abhijit Chakraborty [États-Unis] ; Karen Thudium Mueller [États-Unis] ; Edmund K. Waller [États-Unis]Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
000034 (2020) Gaëlle Vial [France] ; Anaïs De Pouilly [France] ; Laetitia Scouppe [France] ; Bruno Pereira [France] ; Claire Daien [France] ; Cédric Lukas [France] ; Adeline Ruyssen-Witrand [France] ; Pascale Vergne-Salle [France] ; Christophe Richez [France] ; Anne Tournadre [France]Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score.
000072 (2019) Olivier Vittecoq [France] ; Sandra Desouches [France] ; Marie Kozyreff [France] ; Julia Nicolau [France] ; Sophie Pouplin [France] ; Pascal Rottenberg [France] ; Nicolas Sens [France] ; Thierry Lequerre [France] ; Gilles Avenel [France]Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study
000198 (2018) K L Winthrop [États-Unis] ; X. Mariette [France] ; J T Silva [Espagne] ; E. Benamu [États-Unis] ; L H Calabrese [États-Unis] ; A. Dumusc [Suisse] ; J S Smolen [Autriche] ; J M Aguado [Espagne] ; M. Fernández-Ruiz [Espagne]ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
000218 (2017-11-03) Alain Saraux [France] ; René-Marc Flipo [France] ; Bernard Combe [France] ; Jacques Tebib [France] ; Christelle Baffie [France] ; Isabelle Idier [France] ; Alain Cantagrel [France]Factors influencing the prescription of Tocilizumab alone or in combination with Dmards in rheumatoid arthritis patients in a real life setting. Pooled analysis of 2 observational studies.
000220 (2017-07-14) Jacques Morel [France] ; Arnaud Constantin [France] ; Gabriel Baron [France] ; Emmanuelle Dernis [France] ; René-Marc Flipo [France] ; Stéphanie Rist [France] ; Bernard Combe [France] ; Jacques-Eric Gottenberg [France] ; Thierry Schaeverbeke [France] ; Martin Soubrier [France] ; Olivier Vittecoq [France] ; Maxime Dougados [France] ; Alain Saraux [France] ; Xavier Mariette [France] ; Philippe Ravaud [France] ; Jean Sibilia [France]Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE
000245 (2017) Jacques Morel [France] ; Arnaud Constantin [France] ; Gabriel Baron [France] ; Emmanuelle Dernis ; René Marc Flipo ; Stéphanie Rist ; Bernard Combe [France] ; Jacques Eric Gottenberg [France] ; Thierry Schaeverbeke ; Martin Soubrier ; Olivier Vittecoq ; Maxime Dougados [France] ; Alain Saraux ; Xavier Mariette [France] ; Philippe Ravaud [France] ; Jean Sibilia [France]Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.
000276 (2017) René-Marc Flipo [France] ; Jean-Francis Maillefert [France] ; Pascal Chazerain [France] ; Isabelle Idier [France] ; Mathieu Coudert [France] ; Jacques Tebib [France]Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study
000384 (2015) Hubert G. Nü Lein [Allemagne] ; Rieke Alten [Allemagne] ; Mauro Galeazzi [Italie] ; Hanns-Martin Lorenz [Allemagne] ; Michael T. Nurmohamed [Pays-Bas] ; William G. Bensen [Canada] ; Gerd R. Burmester [Allemagne] ; Hans-Hartmut Peter [Allemagne] ; Karel Pavelka [République tchèque] ; Melanie Chartier [France] ; Coralie Poncet [France] ; Christiane Rauch [Allemagne] ; Manuela Le Bars [France]Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
000387 (2015) Rachel Audo [France] ; Claire Daien [France] ; Laura Papon [France] ; Cédric Lukas [France] ; Olivier Vittecoq [France] ; Michael Hahne [France, Pays-Bas] ; Bernard Combe [France] ; Jacques Morel [France]Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort
000445 (2014) Claire I. Daïen [France] ; Jacques Morel [France]Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
000468 (2014) E. Mahé [France] ; Z. Reguiai ; H. Barthelemy ; N. Quiles-Tsimaratos ; G. Chaby ; C. Girard ; E. Estève ; F. Maccari ; V. Descamps ; J. Schmutz ; E. Begon ; P. Bravard ; H. Maillard ; T. Boyé ; A. Beauchet [France] ; M. SigalEvaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross‐sectional study
000582 (2013) J.-E. Gottenberg [France] ; C. Mpofu [Suisse] ; W. Bensen [Canada] ; A. Rubbert-Roth [Allemagne] ; F. Irazoque [Mexique] ; V. Martínez Taboada [Espagne] ; C. Chung [États-Unis] ; L. Hinsch-Gylvin [Suisse] ; C. Ferri [Italie] ; P. Emery [Royaume-Uni]AB0541 Factors associated with selection of rituximab vs alternative TNF inhibitor (TNFI) following TNFI failure in patients with rheumatoid arthritis: Sub-analysis of switch-RA, a global, comparative effectiveness observational study
000589 (2013) M. Couderc [France] ; S. Mathieu [France] ; M. Soubrier [France]AB0310 Predictive factors for the response to rituximab in rheumatoid arthritis: Results from a french university hospital
000742 (1970-01-01) Laure Gossec [France] ; Ghislaine Steinberg ; Stephanie Rouanet [France] ; Bernard Combe [France]Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
000752 (????) Laure Gossec [France] ; Ghislaine Steinberg [France] ; Stephanie Rouanet [France] ; Bernard Combe [France]Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Title.i -k "factors" 

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Title.i  \
                -Sk "factors" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Title.i
   |clé=    factors
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021